AIM2 and nasopharyngeal carcinoma: The AIM2 expression is highly reduced in melanoma, colorectal cancer, and prostate cancer, whereas it is upregulated in hepatocellular carcinoma, nasopharyngeal cancer, and oral squamous cell carcinoma.